Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives $215.20 Consensus Target Price from Brokerages

Axsome Therapeutics, Inc. (NASDAQ:AXSM) has received a consensus rating of “Moderate Buy” from the nineteen ratings firms that are presently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating and seventeen have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $216.1176.

AXSM has been the subject of several analyst reports. TD Cowen reaffirmed a “buy” rating on shares of Axsome Therapeutics in a research report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Axsome Therapeutics in a research note on Wednesday, January 21st. Guggenheim raised their price objective on Axsome Therapeutics from $205.00 to $220.00 and gave the stock a “buy” rating in a research report on Tuesday. Wells Fargo & Company lifted their price objective on Axsome Therapeutics from $193.00 to $202.00 and gave the stock an “overweight” rating in a research note on Tuesday. Finally, UBS Group increased their target price on shares of Axsome Therapeutics from $248.00 to $251.00 and gave the company a “buy” rating in a research report on Tuesday.

Key Stories Impacting Axsome Therapeutics

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Wolfe Research initiated coverage with an “Outperform” and $230 price target (about 40% upside), providing a fresh bullish catalyst and likely driving buy-side interest. Wolfe Research initiates coverage of Axsome Therapeutics (AXSM) with outperform recommendation
• Positive Sentiment: Needham & Company also issued a Buy rating, adding to growing analyst bullishness that can support the share price if momentum continues. Axsome Therapeutics (NASDAQ:AXSM) Earns Buy Rating from Needham & Company LLC
• Positive Sentiment: Axsome announced dosing the first patient in the CLARITY Phase 3 trial of solriamfetol for MDD with excessive daytime sleepiness — a meaningful pipeline milestone that could drive long-term value if trials progress. Axsome Therapeutics Initiates CLARITY Phase 3 Trial…
• Positive Sentiment: Coverage noting Axsome’s stronger representation in Nasdaq index funds and related inflows may have supported upside pressure earlier in the session. Axsome (NASDAQ:AXSM) Reaches New Heights In The Nasdaq Index Fund
• Neutral Sentiment: Axsome will participate in multiple investor conferences in March (TD Cowen, etc.), which increases institutional visibility but is typically a neutral near-term event unless new guidance or data are released. Axsome Therapeutics to Participate in Upcoming Investor Conferences
• Neutral Sentiment: Reported short-interest data in the feed is effectively zero/invalid for February (no meaningful days-to-cover), so it provides no clear explanatory signal for today’s move.
• Negative Sentiment: Q4 showed strong revenue growth (surge on Auvelity sales) but a wider-than-expected loss — a mixed earnings print that can prompt profit-taking despite top-line strength. Analysts and investors may be parsing margins, guidance and cash/burn assumptions after the report. AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales

Insider Activity

In other news, insider Ari Maizel sold 7,500 shares of the stock in a transaction on Wednesday, January 21st. The shares were sold at an average price of $184.44, for a total transaction of $1,383,300.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mark E. Saad sold 37,577 shares of the business’s stock in a transaction dated Wednesday, December 31st. The shares were sold at an average price of $165.18, for a total value of $6,206,968.86. Following the completion of the transaction, the director directly owned 10,002 shares in the company, valued at $1,652,130.36. This represents a 78.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 308,874 shares of company stock valued at $51,390,805. Company insiders own 22.30% of the company’s stock.

Institutional Trading of Axsome Therapeutics

Large investors have recently modified their holdings of the stock. Wellington Management Group LLP boosted its position in shares of Axsome Therapeutics by 84.1% during the 3rd quarter. Wellington Management Group LLP now owns 1,334,560 shares of the company’s stock worth $162,082,000 after purchasing an additional 609,516 shares in the last quarter. Norges Bank acquired a new position in Axsome Therapeutics during the 4th quarter worth approximately $90,490,000. Price T Rowe Associates Inc. MD raised its stake in Axsome Therapeutics by 45.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,509,870 shares of the company’s stock worth $275,763,000 after buying an additional 472,422 shares during the period. Invesco Ltd. boosted its holdings in Axsome Therapeutics by 73.3% in the third quarter. Invesco Ltd. now owns 990,557 shares of the company’s stock worth $120,303,000 after acquiring an additional 419,008 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. grew its stake in Axsome Therapeutics by 831.3% in the second quarter. Adage Capital Partners GP L.L.C. now owns 447,000 shares of the company’s stock valued at $46,662,000 after acquiring an additional 399,000 shares during the period. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Stock Down 3.4%

Shares of AXSM opened at $164.22 on Thursday. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.50 and a current ratio of 1.55. Axsome Therapeutics has a 52 week low of $86.99 and a 52 week high of $191.50. The stock has a market capitalization of $8.40 billion, a price-to-earnings ratio of -44.50, a PEG ratio of 36.15 and a beta of 0.40. The stock has a fifty day moving average of $175.23 and a 200-day moving average of $145.53.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings results on Monday, February 23rd. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.70) by $0.14. Axsome Therapeutics had a negative return on equity of 232.61% and a negative net margin of 28.69%.The company had revenue of $196.00 million for the quarter, compared to analysts’ expectations of $191.33 million. Axsome Therapeutics’s revenue for the quarter was up 65.0% on a year-over-year basis. As a group, sell-side analysts anticipate that Axsome Therapeutics will post -2.79 earnings per share for the current fiscal year.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.